The Combination of Genistein and Imatinib has an Increased Effect on Cell Proliferation Inhibition in Philadelphia Positive Leukemia Cell Lines

Ebrahim Azizi1,2*, Alireza Biglari1, Ali Kian Saei2, Saeid Amanpour2, Samad Muhammadnejad2, Mahnaz Haddadi2, Mojtaba Saffari2, Reza Shirkoohi2

A B S T R A C T

Background: This study investigated the possible role of Genistein as a combination with Imatinib in controlling leukemia cell line proliferation.

Methods: Three cell lines, K562, Kcl22, and CCRF, were cultured and analyzed for MTT, LDH, apoptosis, and cycle cell gene expression in the presence of different dosages of Imatinib and Genistein in combination or separately.

Results: Data has shown a decrease in proliferation and an increase in apoptosis activity during combination treatment. LDH assay has shown no additional toxicity due to Genistein consumption in combination therapy. Analysis of the expression of responsible genes for cell cycle demonstrated both G1 (p53, p21 upregulation) and G2 (cdc25c downregulation) inhibitory effect in combination treatment.

Conclusion: Altogether, this study suggests that the combination treatment of Imatinib and Genistein for leukemia cells resistant to Imatinib can increase treatment efficiency.

Keywords: Cell cycle, Genistein, Imatinib, leukemia, Philadelphia chromosome
INTRODUCTION:

Leukemia, neoplasia of hematopoietic cells, has various types with several degrees of malignancy and prognosis (1). Among the prognostic characteristics which have a significant role in the therapeutic plan, alterations in oncogenes have great importance (2). Gene translocations, such as AML1-ETO, PML-RARA, BCR-ABL (known as Philadelphia chromosome), are among such alterations and common in leukemia (3).

Philadelphia chromosome is a mutual translocation caused by the fusion of breakpoint cluster (BCR) gene from chromosome 22 and ABL1 gene (Abelson Tyrosine Kinase) of chromosome 9 (3). The translocation will lead to constitutive activation of the ABL1 oncogene with its tyrosine kinase activity (4). Depending on the part of the BCR breaking point participating in fusion with ABL1, three different isoforms of P190, P210, P230 can be created. ABL on chromosome 9 has 12 exons, with a breaking point always between exon 1 and 2. The fusion gene always contains the ABL1 gene started from the second exon (5). When ABL kinase, located in the nucleus, combines with the BCR gene, it moves to the cytoplasm. It activates some signaling pathways which cause cell proliferation enhancement and skip from apoptosis (6).

Formerly known as STI571 Gleevec, Imatinib mesylate is used as a tyrosine kinase inhibitor by inhibiting phosphate transportation on a substrate that stops phosphorylation in BCR-ABL1 (7, 8). On the other hand, mechanisms such as gene fusion overexpression, structural alteration in BCR-ABL interfering with drug interaction, alterations in ATP binding domain, chromosomal translocation other than BCR-ABL (like SRC), and expression of proteins which efflux Imatinib from the cell can cause Imatinib resistance (9).

Flavonoids have many different characteristics, such as anti-atherosclerosis, anti-inflammatory, anti-thrombosis, anti-tumorogenesis, anti-viral, and anti-osteoporosis to remove free radicals in cancer (10, 11). They are subgrouped into four classes (12). Genistein belongs to the Flavone class of Flavonoids (12).

Genistein can naturally be found in soya, green tea, onion, etc., and has an anti-cancer effect by inhibiting Topoisomerase II, angiogenesis, tyrosine kinase activity, oncogenic product activity, and prostaglandin synthesis (13). One of the other features of this herbal combination is the inhibitory effect of some tyrosine kinases, including epidermal growth factor, ATM, P13K, and CRKL, which are also downstream of signaling by BCR-ABL recombinant gene (14, 15). Genistein affects 253 JBV bladder cancer cell lines. It causes cell cycle arrest in the G2-M stage through downregulation of cdc25c, cdk1, and cyclin B1 expression (16). Moreover, it causes apoptosis by inducing DNA destruction, enhancing digested caspase 3, and downregulation of Bcl2 accompanied by Bax upregulation (17).

It is well known that Genistein is an agent for cell growth inhibition in the G2-M stage and also has some tyrosine kinase inhibition characteristics. Thus, in this study, it is proposed that the combination of Imatinib, with an inhibitory effect on the G1-S stage, and Genistein, with an inhibitory effect on G2-M, can have an inhibitory effect on leukemia cells, especially on Philadelphia positive cells.

Material and methods

Cell lines

K562 as a Philadelphia positive CML cell line, KCL22 as a Philadelphia positive ALL cell line, and CCRF-CEM as a Philadelphia negative ALL cell line were provided by the Pasteur Institute of Iran. The cell lines were cultured using RPMI 1640 containing 10% FBS in 37 °C and a 5% CO2 incubator.

Imatinib and Genistein treatment

The cells were treated with Imatinib mesylate (Novartis, Basel, Switzerland) and Genistein (Sigma, USA) as a single or combination treatment with different dosages of 25, 50, 75, 100, 150, and 200 μM of Imatinib and Genistein. In the combination treatment, the cells were treated with a constant dosage of 100 μM Imatinib which was used as a maximum dosage in many articles (18-20) in combination with different dosages of 25, 50, 75, 100, 150, 200 μM of Genistein. The treatment durations were 24 and 48 hours. Then the cells were pre-
pared for further experiments as mentioned below.

**MTT assay**
A number of $10^4$ cells were seeded in each well of 96 well plates and incubated at 37 °C for 24 hours. Samples were considered triplicate. Then, the cells were treated with different dosages of Imatinib and interested genes. The amount of 10 μl of MTT solution (Roche, USA, 11465007001) in a concentration of 5 mg/ml was added to each well in different periods (24, 48 hours). The procedure was followed accordingly to the manual protocol. The absorbance was recorded at 550-570-590-600 nm by ELISA reader (BioTek, USA, Gen5 power wave xs2).

**LDH assay**
Cell toxicity was studied using Lactate Dehydrogenase (LDH) toxicity assay (Sigma, USA). A number of $10^4$ cells were seeded in 96 well plates incubated at 37 ºC and 5% CO2 for 24 hours. As mentioned before, the cells were treated with different dosages of Imatinib and Genistein for 24 and 48 hours and then prepared for LDH assay based on the manual protocol. The absorbance was recorded at 490-500 nm by ELISA reader (BioTek, USA, Gen5 power wave xs2).

**Apoptosis**
A number of $1.5 \times 10^4$ cells were seeded in 96 well plates and incubated at 37 °C and 5% CO2 for 24 hours. According to the manual protocol, the cells were treated with different dosages of Imatinib and Genistein for 24 hours and prepared for caspase assay. The absorbance was recorded at 450-500 nm by ELISA reader (BioTek, USA, Gen5 power wave xs2).

**RNA extraction and RT-PCR**
RNA was extracted from 106 treated cells using a high pure RNA isolation kit (Roche, USA, 1182865001) based on the manual protocol. The quantity and quality of extracted RNA were confirmed by Nanodrop (USA, Thermo model 2000) and 1.5% agarose gel electrophoresis. According to the manual protocol, cDNA synthesis was made from 1-2 μg of the extracted RNA using an easy cDNA synthesis kit (Pars Tous, Iran).

Real-time PCR was performed using 2μl of cDNA and 1μM of each primer (Table 1) added to primer mix (1μM) and syber green master mix (Takara, Japan) using RT-PCR instrument (Rotor gene Q, Qiagen, USA). The program for reaction started by denaturation step at 95

---

**Table 1: Primers used for quantitative RT-PCR**

| Name of Gene | Primer | Sequence | Size of product |
|--------------|--------|----------|-----------------|
| P53          | Forward| 5'-TCT CCC CAG CCA AAG AAG AAA-3' | 105             |
|              | Reverse| 5'-TTG CAA GCC CTC ATT CAG CTC-3' |                 |
| P21          | Forward| 5'-CAA AGG CCC GCT CTA CAT CTT-3' | 171             |
|              | Reverse| 5'-AGG AAC CTC TCA TTC AAC CGC-3' |                 |
| CDC2         | Forward| 5'-GCA CCC ATG TCA AAA ACT TGG-3' | 105             |
|              | Reverse| 5'-GGA TGA TTC AGT GCC ATT TTG C-3' |                 |
| CDC25C       | Forward| 5'-TTT TTC CAA GGT ATG TGC GCT G-3' | 102             |
|              | Reverse| e 5'-TGG AAC TTC CCC GAC AGT AAG G-3' |                 |
°C for 10 minutes followed by 35 cycles of initiation at 95 °C for 10 seconds, annealing at 56 °C for 15 seconds, elongation at 72 °C for 20 seconds, and a single final step at 58 °C for 90 seconds. At the end of the program, the melting curve was checked and data analyzed by CT calculation using REST software (Qiagen, USA). Untreated cells were used as the negative control. Cells treated with an average dosage of Imatinib were used as the positive control. All primers were designed using primer3 (version 0.4.0) online program (https://bioinfo.ut.ee/primer3-0.4.0/) and were confirmed by primer blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast) to avoid the nonspecific product. Concerning p53 with different isoforms, the melting curve has shown only one clear peak corresponding to the selected product, confirmed by 1.5% agarose gel electrophoresis.

Statistical analysis
Data for the gene amplification and relative fold change was analyzed by Rotor-Gene Q and REST software (Qiagen, USA), respectively. All data were produced as triplicates and analyzed for the association using SPSS (Statistical Package for the Social Sciences) software (IBM, Chicago, USA), calculating the p-value and employing the Student’s t-test.

RESULTS

MTT
The effect of Imatinib on all three cell lines has shown that it causes a decrease in cell viability in a dosage-dependent manner compared with untreated cells (Figure 1). The same results were observed in Genistein treatment in all three cell lines with slight differences. Combination therapy with 100 uM of Imatinib with different dosages of Genistein has shown more effective decrement in cell viability, in which data were significant in all three cell lines during treatment with the highest dosage of Imatinib and Genistein in the combination therapy (p<0.05, p<0.01, p<0.01 for KCL22, K562, CCRF, respectively).

Figure 1. MTT assay of Imatinib, Genistein, and combination therapy as mentioned in the materials and methods. Combination therapy has more effect in the suppression of cell proliferation in a dosage-dependent manner (totally p<0.05 in all different dosages showing a significant effect of Genistein when added to the Imatinib in A) Kcl22, B) K562, and C) CCRF cell lines.
As illustrated in Figure 2, Imatinib and Genistein toxicity was compared in all three cell lines. The critical point was that adding Genistein to Imatinib treatment in all three cell lines did not increase the toxicity of Imatinib.

Caspase3

Based on Figure 3, the caspase activity increased more during the combination therapy in all three cell lines than single treatment with Imatinib. This was more significant in K562 and CCRF (p<0.01, p<0.001 respectively) cell lines demonstrating that the combination therapy is effective in cell lines without Philadelphia chromosome, suggesting different mechanisms for Genistein as a combination for apoptosis and cell growth suppression other than the possible ABL1 anti-tyrosine kinase inhibitory role.

Real-Time PCR

In the KCL22 cell line, treatment with Imatinib and Genistein and combination treatment has demonstrated increased p53, p21, and cdc2 gene expression followed by cdc25c downregulation (Figure 4A). Combination therapy has shown to be higher in p53 and p21 gene expression compared to Imatinib single treatment (p<0.01, p=0.01 respectively), while downregulation in cdc25c

Figure.2. LDH assay of Imatinib, Genistein, and combination therapy as mentioned in the materials and methods. Control cells with maximum release of LDH were determined as cut-off lines (100). Data has shown no additional toxicity of Genistein in combination therapy in all three cell lines; A) Kcl22, B) K562, and C) CCRF.

Figure.3. Apoptotic activity was observed by caspase activity. As it is shown, the combination has a dramatic effect on apoptosis in all three cell lines.

LDH

As illustrated in Figure 2, Imatinib and Genistein toxicity was compared in all three cell lines. The critical point was that adding Genistein to Imatinib treatment in all three cell lines did not increase the toxicity of Imatinib.
expression was also more significant in combination treatment \((p=0.01)\). In K562 cell lines, while single and combination therapy caused p53 and p21 overexpression, cdc2 overexpression was only observed in Imatinib single treatment, but downregulation was shown in Genistein and combination therapy. Genistein seems to have the dominant effect on combination therapy. Cdc25c expression was downregulated during the treatment of cell lines with Imatinib. The downregulation was more prominent in Genistein treatment and even more with combination treatment compared to Imatinib single treatment \((p<0.01)\) (Figure 4B). Concerning CCRF cell line, combination treatment caused a dramatic elevation in p53, p21, and cdc2 \((p<0.001)\), and downregulation in cdc25c \((p=0.01)\) (Figure 4C).

DISCUSSION

This study proposes that Genistein, a flavonoid drug with a protein kinase inhibitory function, could be combined with Imatinib (21, 22). It has been demonstrated that Genistein could have an inhibitory effect on cell growth and proliferation (23). The estrogenic effect of Genistein usually occurs in lower dosages, which can inhibit apoptosis and increase cell proliferation. In comparison, higher dosages of Genistein usually have an inhibitory effect on cell proliferation, antioxidant activity, and apoptosis induction in cancer cells (24).

Previous studies have demonstrated that kinase activity inhibition of BCR-ABL1 by Imatinib can cause G1 arrest in cell cycle analysis (25). Treatment with Imatinib will cause the activation of tumor suppressors such as P16NK4 and Rb1. This is followed by the binding of these proteins to cyclin-dependent kinases such as CDK4, 6, leading to overexpression of CDK inhibitor families such as Cip/Kip like p21waf1, p27kip1, and p53 and binding to CDK2/Cyclin E, S complex, which eventually leads to G1 cell cycle arrest (26, 27). All data from our studies show the same pattern in both Philadelphia positive K562 and KCL22. It has been demonstrated that Genistein has an

![Figure 4. Expression of genes with essential roles in cell cycle control using quantitative RTPCR in A) Kcl22, B) K562, and C) CCRF cell lines.](image-url)
essential role in the G2/M phase of cell cycle arrest in many cancer cells such as prostate, breast, and testis cancer (28). Also, it has been demonstrated that the most critical factor for the transition of growing cells from G2 to M is the activation of cyclin B1/cdc2 (29).

When the cells move to the G2 stage, the cyclin B1 that binds to cdc2 increases (30, 31). Also, the basic phosphorylation of cdc2 has a critical role in arresting or moving cells into the G2 stage. If Tyr 15 in the ATP binding domain of cdc2 is phosphorylated by Wee1 kinase, it causes inactivation of cdc2 followed by G2 cell cycle arrest. However, if Tyr 15 is dephosphorylated by cdc25c, it leads to the formation of active complex cdc2/cyclin B1 and transfers to mitosis or M stage (32, 33). Several studies have shown that Genistein causes a decrement in cdc25c activity and stabilization of Tyr 15 cdc2 phosphorylation and G2 stage cell cycle arrest (34).

We have hypothesized that using the combination of Imatinib and Genistein as the effector of the G1 and G2 cell cycle will have a supportive effect on cell suppression and apoptosis caused by Imatinib. It has been shown that the combination has a repressor effect on cdc2 expression caused by Imatinib and even down-regulation of cdc25c in Philadelphia positive cell lines, which indicates more focus on the G2 phase.

During Imatinib treatment, the expression of Cdk inhibitors, such as P21 waf/cip1, increases in G1. This is possibly related to P53 for G1 cell arrest. In the case of Genistein, it has been shown that P21 could be associated with Tyr 15 Cdc2, in which overexpression of P21 decreases the expression of cdc2. This can prevent active Cyclin B1/cdc2 complex formation, or if it is formed, lack of kinase activity causes G2 stage cell cycle arrest (35). Also, it has been shown that Genistein could inhibit the kinase activity of cdc2 in some cancer cell lines like MDA-MB-468 (36).

In line with the previous studies, this study demonstrates that P53 and P21 increase during treatment with Genistein, which was more evident in Philadelphia positive K562, CML cell line than ALL cell line KCL22. Also, the expression of p21 and p53 were higher. In addition, the expression of Cdc2 and Cdc25c decreased more obviously in K562 than in KCL22. Altogether, it demonstrates that Genistein is an inhibitor of the G2 step.

Cell treatment with Imatinib has been shown to enhance p53 and p21 expression, which, unlike Genistein, it is more evident in the case of p53 than p21 (37). Imatinib has little effect on Cdc2 and Cdc25c expression. Thus, it may not have any role in cell cycle arrest in the G2 stage through Cdc2. Our study demonstrated that concomitant use of Imatinib and Genistein increases the expression of p53 and p21 in both K562 and KCL22 cell lines. In contrast, the expression of Cdc25c declined. Since the enhancement of both G1 and G2 arrest due to the increase in the expression of p53 and p21 was observed more in combination treatment, it could be suggested that the combination of Genistein and Imatinib is effective on tumor suppressors and CDK inhibitor expression in both G1 and G2 stages compared to Imatinib treatment alone. On the other hand, downregulation in Cdc2, which has a vital role in G2 cell cycle arrest, is more evident during concomitant treatment than in Imatinib alone. More decrement in Cdc25c during concomitant treatment causes an increase in G2 cell cycle arrest. Moreover, by investigating the path of Caspase 3 breakage, an effective caspase both extrinsically and intrinsically, we could demonstrate the effective role of Genistein and Imatinib concomitant treatment. It is well shown that Imatinib causes apoptosis in CML cancer cell line K562 through activation of the intrinsic path of apoptosis and activation of pro-apoptotic molecules such as Caspase 9 (33). Also, other studies have shown that treatment with Genistein leads to an increase in apoptosis (38). Genistein can increase the level of Bax protein, a pro-apoptotic protein, and decrease Bcl2 protein, an anti-apoptotic protein (39). In this study, it has been demonstrated that the breaking amount of Caspase 3 during concomitant treatment of Imatinib and Genistein is more than treatment with Imatinib alone, suggesting that more cells are arrested in the cycle and going through apoptosis. This was more obvious in CML than ALL cell lines. Induction of apoptosis and inhibition of the cell cycle are critical mechanisms of a drug used for cancer treatment.
CONCLUSION
We have found that concomitant treatment with Imatinib mesylate, an established drug, and Genistein, an herbal drug with no toxic effect, could inhibit Philadelphia positive leukemic cell proliferation more effectively than single treatment, even in increasing G1 and G2 stage of cell cycle arrest. Also, based on our results, the combination treatment should be performed in the preclinical stage by using different leukemia cell lines, preferably tyrosine kinase-dependent immortalities (such as Philadelphia), for new hope in cases with drug resistance or relapses.

Acknowledgments
The authors would like to thank Seyed Muhammed Hussein Moussavinasab for his sincere cooperation in editing this text. Also, they would like to thank Tayebeh Sabokbar and Elnaz Aghdami for their technical assistance and valuable comments.

This study was supported by the Cancer Research Center of Tehran University of Medical Sciences and Zanjan University of Medical Sciences.

CONFLICT OF INTEREST
The authors have no conflict of interest.

REFERENCES
1. Pokharel M. Leukemia: A Review Article. IJARPB. 2012;1(3):397-407.
2. Yang J, Schiffer C. Genetic Biomarkers in Acute Myeloid Leukemia. Expert Review of Hematology. 2012;5(4):395-407.
3. Gonon-Demoulain R, Goldman JM, Nicolini FE. [History of chronic myeloid leukemia: a paradigm in the treatment of cancer]. Bull Cancer. 2014 Jan 1;101(1):56-67.
4. Langie SA, Koppen G, Desaulniers D, Al-Mulla F, Al-Temaimi R, Amedei A, et al. Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis. 2015 Jun;36 Suppl 1:S61-88.
5. Ma I, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Science translational medicine. 2014 Sep 3;6(252):252ra121.
6. Gustafson D, Fish JE, Lipton JH, Aghel N. Mechanisms of Cardiovascular Toxicity of BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Curr Hematol Malig Rep. 2020 Feb;15(1):20-30.
7. O’Hare T, Deininger M, Eide C, Clackson T, Druker B. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res. 2011;17(2):212-21.
8. Hochhaus A, O’Brien S, Guilhot F, Druker B, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-61.
9. Sivenn KS, Prabhhu KS, Achkar JW, Kuttikrishnan S, Shyam S, Khan AQ, et al. Role of Non Receptor Tyrosine Kinases in Hematological Malignancies and its Targeting by Natural Products. Molecular cancer. 2018 Feb 19;17(1):31.
10. Rizzo G, Baroni L. Soy, Soy Foods and Their Role in Vegetarian Diets. Nutrients. 2018 Jan 5;10(1).
11. Zhang H, Gordon R, Li W, Yang X, Pattanayak A, Fowler G, et al. Genistein treatment duration effects biomarkers of cell motility in human prostate. PLoS One. 2019;14(3):e0241078.
12. Dong X, Xu W, Sikes RA, Wu C. Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone. Food Chem. 2013 Dec 1;141(3):1923-33.
13. Roy Choudhury S, Karmakar S, Banik N, Ray S. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. Invest New Drugs. 2010;28(6):812-24.
14. Privat M, Aebel C, Arnaud S, Communal Y, Ferrara M, Bignon Y, AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines. Anticancer Res. 2010;30(6):2049-54.
15. Ratovitski EA. Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression. Current genomics. 2017 Apr;18(2):175-205.
16. Kim SH, Kim CW, Jeon SY, Go RE, Hwang KA, Choi KC. Chemopreventive and chemotherapeutic effects of genistein, a soy isoflavone, upon cancer development and progression in preclinical animal models. Laboratory animal research. 2014 Dec;30(4):143-50.
17. Ismail I, Kang K, Kim J, Sohn Y. Genistein induces G2/M cell cycle arrest and apoptosis in rat neuroblastoma B135 cells; involvement of p21waf1/cip1, Bax and Bcl-2. Korean J Pathol. 2006;40(5):339-47.
18. Boutilir J, Panajatovic MV, Frechard T, Roos NJ, Krahnenbuhl S. Imatinib and Dasatinib Provoke Mitochondrial Dysfunction Leading to Oxidative Stress in C2C12 Myotubes and Human RD Cells. Front Pharmacol. 2020;11:1106.
19. Popow-Wozniak A, Wozniakowska A, Kaczmarek L, Malicka-Blaszkiewicz M, Nowak D. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration. Eur J Pharmacol. 2011 Sep;607(1-3):66-73.
20. Eadie LN, Hughes TP, White DL. ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. PLoS One. 2016;11(8):e0161470.
21. Seo Y, Kim B, Chun S, Park Y, Kang K, Kwon, TG., Appoptotic effect of genistein , Biochanin A and Apigenin on LNCap and PC3 cells by P21 through transcriptional inhibition of Polo-Like Kinase1. J KOREAN Med sci. 2011;26(11):1489-94.
22. Erguven M, Karakulak T, Diril MK, Karaca E. How Far Are We from the Rapid Prediction of Drug Resistance Arising Due to Kinase Mutations? ACS Omega. 2021 Jan 19;6(2):1254-65.
23. Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, et al. Suppressor Genes in Prostate Cancer Cells by Epigenetic Genistein Induces the p21WAF1/CIP1 and p16INK4a Tumor
Mechanisms Involving Active Chromatin Modification. Cancer Res. 2008;68(8):2736-44.

24. Berner C, Aumüller E, Gnauk A, Nestelberger M, Just A, Haslberger A. Epigenetic control of estrogen receptor expression and tumor suppressor genes is modulated by bioactive food compounds. Annals of Nutrition & Metabolism. 2011;57(3-4):183-9.

25. Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, et al. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther. 2014 May;13(5):1155-69.

26. Lee Y, Park O. Soybean isoflavone genistein regulates apoptosis through NF-kappaB dependent and independent pathways. Exp Toxicol Pathol. 2013;65(1-2):1-6.

27. Sferrazza G, Corti M, Brusotti G, Pierimarchi P, Temporini C, Serafino A, et al. Nature-derived compounds modulating Wnt/ beta-catenin pathway: a preventive and therapeutic opportunity in neoplastic diseases. Acta Pharm Sin B. 2020 Oct;10(10):1814-34.

28. Mahmoud AM, Yang W, Bodland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. The Journal of steroid biochemistry and molecular biology. 2014 Mar;140:116-32.

29. Yan G, Zou F, Dang B, Zhang Y, Yu G, Liu X, et al. Genistein-induced mitotic arrest of gastric cancer cells by downregulating KIF20A, a proteomics study. Proteomics. 2012;12(14):2391-9.

30. Sánchez Y, Amrán D, Fernández C, de Blas E, Aller P. Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK). Int J Cancer 2008. 2008;123(5):1205-14.

31. Sampaio MM, Santos MLC, Marques HS, Goncalves VLS, Araujo GRL, Lopes LW, et al. Chronic myeloid leukemia from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol. 2021 Feb 24;12(2):69-94.

32. Mahon F, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, et al. Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer research. 2008;68(23):9809-16.

33. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Molecular cancer. 2018 Feb 19;17(1):49.

34. Pocaly M, Lagarde V, Etienne G, Ribelj J, Claverol S, Bonneu M, et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronicmyeloid leukemia. Leukemia. 2007;21(1):93-101.

35. Drullion C, Lagarde V, Gioia R, Legembre P, Priault M, Cardinaud B, et al. Mycophenolic Acid overcomes imatinib and nilotinib resistance of chronic myeloid leukemia cells by apoptosis or a senescent-like cell cycle arrest. Leukemia research and treatment. 2012;2012:861301.

36. Lin YL, Roux B. Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases. J Am Chem Soc. 2013 Oct 2;135(39):14741-53.

37. Ferrandiz N, Caraballo J, Albajar M, Gomez-Casares M, Lopez-Jorge C, Blanco R, et al. p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells. Cancer lett. 2010;292(1):133-9.

38. Vologzhinina AV, Ushakov IE, Korlyukov AA. Intermolecular Interactions in Crystal Structures of Imatinib-Containing Compounds. Int J Mol Sci. 2020 Nov 26;21(23).

39. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: The suicide solution for delaying cancer growth. Carcinogenesis. 2007;28(2):233-9.